Paul Nguyen, MD
Radiation Oncology · Boston, MANPI 1750315743
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.7%), consulting fees and other — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 71.9% of it on its own, with 10 other manufacturers making up the rest. Among radiation oncology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 301 payments — averaging $2394.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$518K
- Janssen Research & Development, LLC$96K
- Augmenix, Inc.$54K
- Bayer$21K
- Novartis$12K
- Janssen Global Services, LLC$9K
- plus $11K from 5 others
Across 74 payments — averaging $63,349 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$4.7M
- Novartis Pharma AG$1K
What the payments were for
- Consulting fees$304,47642%
- Speaking & faculty fees$372,78852%
- Travel & lodging$13,2272%
- Food & beverage$3,2830%
- Ownership interest$10,6321%
- Other$16,3622%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 231 | $518,008 |
| Janssen Research & Development, LLC | 23 | $95,969 |
| Augmenix, Inc. | 3 | $54,370 |
| Bayer | 23 | $20,945 |
| Novartis | 10 | $11,926 |
| Janssen Global Services, LLC | 3 | $8,640 |
| Astellas Pharma Global Development | 1 | $5,627 |
| Janssen Scientific Affairs, LLC | 2 | $2,140 |
| Blue Earth Diagnostics | 3 | $2,057 |
| Amgen | 1 | $1,029 |
| Accuray Incorporated | 1 | $56 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SpaceOAR VUE System - 10mL$245,369
- GENERAL BPH$100,764
- SpaceOAR System$84,155
- SPACEOAR VUE$59,469
- SPACEOAR$54,370
- GENERAL - THERAPIES$24,583
- Nubeqa$20,459
- Xofigo$13,163
- Erleada$9,576
- XTANDI$5,627
- Lutathera$2,900
- Axumin$1,700
- POSLUMA$357
- REZUM$107
How this compares
$720,768 in reported general payments places this provider in the 95th percentile of 200 radiation oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 17 | $219 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Boston
- Peter OrioBoston$1.8M
- Jason EfstathiouBoston$156K
- Jonathan SchoenfeldBoston$53K
- Martin KingBoston$37K
- Raymond MakBoston$36K
- Shannon MacdonaldBoston$33K
- Nima AghdamBoston$29K
- Rachel JimenezBoston$28K
- Theodore HongBoston$24K
- Alice HoBoston$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.